MULTI-SPECIFIC ANTIBODIES TARGETED AT CD3, CD19 AND CD20 AND THEIR USES
Patent Information
- Application Number
- ARP20250100164
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-23
- Filing Date
- 2025-01-21
- Publication Date
- 2026-07-08
Claims
This description provides multispecific antibodies, the nucleic acid molecules that encode them, expression vectors, and host cells used for the expression of multispecific antibodies. The description also provides methods for preventing and treating cancers by administering multispecific antibodies.
1. An antibody or antigen-binding portion thereof, comprising a CD19-binding residue, a CD3-binding residue, and a CD20-binding residue, wherein: (a) the CD19-binding residue comprises a heavy chain complementarity-determining region (HCDR) 1, an HCDR2, and an HCDR3 comprising the amino acid sequences of SEQ ID Nos. 1, 2, and 3, respectively, and a light chain complementarity-determining region (LCDR) 1, an LCDR2, and an LCDR3 comprising the amino acid sequences of SEQ ID Nos. 4, 5, and 6, respectively; (b) the CD3 binding residue comprises an HCDR1, an HCDR2 and an HCDR3 comprising the amino acid sequences of SEQ ID Nos. 7, 8 and 9, respectively, and an LCDR1, an LCDR2 and an LCDR3 comprising the amino acid sequences of SEQ ID Nos. 10, 11 and 12, respectively;and (c) the CD20-binding residue comprises an HCDR1, an HCDR2, and an HCDR3 comprising the amino acid sequences of SEQ ID Nos. 13, 14, and 15, respectively, and an LCDR1, an LCDR2, and an LCDR3 comprising the amino acid sequences of SEQ ID Nos. 16, 17, and 18, respectively.
109. A nucleic acid sequence encoding the antibody or the antigen-binding portion thereof of any of the preceding claims.
110. A nucleic acid sequence encoding the HC1, HC2, LC1, LC2 or LC3 of the antibody or antigen-binding portion thereof of any of the preceding claims.
111. A nucleic acid sequence encoding HC1, HC2, LC1, LC2 and LC3 of the antibody or antigen-binding portion thereof of any of the preceding claims.
112. A vector comprising the nucleic acid sequence of any of the preceding claims.
113. A host cell comprising the nucleic acid sequence of any of the preceding claims or the vector of any of the preceding claims.
114. A pharmaceutical composition comprising the antibody or the antigen-binding portion thereof of any of the preceding claims and a pharmaceutically acceptable carrier.
115. A method for producing the antibody or the antigen-binding portion thereof of any of the preceding claims, comprising the steps of: (a) growing a host cell comprising a nucleic acid sequence encoding the antibody or the antigen-binding portion thereof under suitable conditions; and (b) isolating the antibody or the antigen-binding portion thereof from the host cell.
116. A method for producing the antibody or the antigen-binding portion thereof of any of the preceding claims, comprising the steps of: (a) growing a host cell comprising a nucleic acid sequence encoding HC1, HC2, LC1, LC2 or LC3 of the antibody or the antigen-binding portion thereof under suitable conditions; and (b) isolating the antibody or the antigen-binding portion thereof from the host cell.
117. A method for producing the antibody or the antigen-binding portion thereof of any of the preceding claims, comprising the steps of: (a) growing a host cell comprising a nucleic acid sequence encoding HC1, HC2, LC1, LC2 and LC3 of the antibody or the antigen-binding portion thereof under suitable conditions; and (b) isolating the antibody or the antigen-binding portion thereof from the host cell.